Sign in Subscribe
Cancer research

MAIA Biotechnology Partners with Roche for Groundbreaking Cancer Treatment Studies

Strategic Insights

— 1 min read

MAIA Biotechnology, a clinical-stage biopharmaceutical company, has entered into a clinical master supply agreement with Roche to investigate the combination of its telomere-targeting agent ateganosine and Roche's checkpoint inhibitor atezolizumab for the treatment of hard-to-treat cancers. The partnership aims to strengthen MAIA's mission to find safe and effective cancer treatments.

Key Takeaways:

  • MAIA's ateganosine, a first-in-class telomere-targeting agent, has shown synergy and effectiveness in combination with Roche's anti-PD-L1 agent atezolizumab in preclinical studies.
  • The partnership will investigate the combination of ateganosine and atezolizumab for the treatment of multiple hard-to-treat cancers, with a focus on non-small cell lung cancer (NSCLC) patients.
  • Ateganosine works by inducing telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death, activating both innate and adaptive immune responses.
  • The sequential treatment with ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory.
  • MAIA's lead program, ateganosine, is currently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
  • MAIA's partnership with Roche is a significant step in the company's mission to develop targeted immunotherapies for cancer treatment.

Statistics:

  • 6-thio-2'-deoxyguanosine (6-thio-dG or 6-thio-THIO) is a modified nucleotide that induces telomerase-dependent telomeric DNA modification.
  • Telomeres, along with telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies.
  • 50-80% of NSCLC patients have telomerase-positive cancer cells.
  • Roche's Tecentriq (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
  • MAIA Biotechnology is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer treatment.

Sources:

  • Businesswire.com: "MAIA Biotechnology, Inc. (NYSE American: MAIA) Enters into a Clinical Master Supply Agreement with Roche for Future Studies"
  • FDA.gov: "TECENTRIQ (atezolizumab)"
  • Genentech.com: "Tecentriq (atezolizumab)"

Read more